NA
VIVO

Navellier & Associates’s Meridian Bioscience Inc VIVO Stock Holding History

Navellier & Associates’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-29,068
Closed -$763K – 350
2021
Q1 		$763K Buy
29,068
+2,747
+10% +$65.3K 0.14% 138
2020
Q4 		$492K Buy
26,321
+3,030
+13% +$56.6K 0.09% 169
2020
Q3 		$395K Buy
23,291
+3,453
+17% +$67.1K 0.09% 163
2020
Q2 		$462K Buy
+19,838
New +$287K 0.11% 139
2017
Q1 		– Sell
-50,463
Closed -$893K – 321
2016
Q4 		$893K Buy
50,463
+8,229
+19% +$145K 0.15% 138
2016
Q3 		$815K Buy
42,234
+10,601
+34% +$207K 0.12% 141
2016
Q2 		$617K Buy
31,633
+13,534
+75% +$265K 0.09% 125
2016
Q1 		$373K Buy
+18,099
New +$357K 0.05% 146

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Navellier & Associates's VIVO Position: Q2 2021 in Review

Navellier & Associates sold out of Meridian Bioscience Inc (VIVO) in Q2 2021, closing a stake of 29,068 shares — an estimated $763K sold.

Navellier & Associates first reported a position in VIVO in Q1 2016 and held it in 8 quarters. The position peaked at $893K in Q4 2016. 189 funds tracked by Wall St. Rank hold VIVO as of Q2 2021.

  • Navellier & Associates reported no remaining Meridian Bioscience Inc position as of Q2 2021 after selling out during the quarter.
  • Navellier & Associates sold 29,068 Meridian Bioscience Inc shares in Q2 2021, an estimated $763K.
  • Navellier & Associates first reported a position in Meridian Bioscience Inc in Q1 2016 and held it in 8 quarters.
  • Navellier & Associates's Meridian Bioscience Inc position peaked at $893K in Q4 2016.
  • 189 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2021.

Based on Navellier & Associates's 13F filing for Q2 2021, filed 9 Aug 2021.